Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis

References

• Atlas ID. International Diabetes Federation (IDF). Brussels, Belgium: International Diabetes Federation; 2013. 2017
   Google Scholar
• Jaacks LM, Siegel KR, Gujral UP, et al. Type 2 diabetes: a 21st century epidemic. Best Pract Res Clin Endocrinol Metab 2016;30:331-43
   PubMed Web of Science ®Google Scholar
• Seuring T, Archangelidi O, Suhrcke M. The economic costs of type 2 diabetes: a global systematic review. Pharmacoeconomics 2015;33:811-31
   PubMed Web of Science ®Google Scholar
• Internal Clinical Guidelines Team. National Institute for Health and Care Excellence: clinical guidelines. Type 2 diabetes in adults: management. London, UK: National Institute for Health and Care Excellence; 2015
   Google Scholar
• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2015;58:429-42
   PubMed Web of Science ®Google Scholar
• Thrasher J. Pharmacologic management of type 2 diabetes mellitus: available therapies. Am J Cardiol 2017;120(1S):S4-S16
   PubMedGoogle Scholar
• Lau J, Bloch P, Schaffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem 2015;58:7370-80
   PubMed Web of Science ®Google Scholar
• Lund A, Knop FK, Vilsboll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med 2014;25:407-14
   PubMed Web of Science ®Google Scholar
• Ahren B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 2017;5:341-54
   PubMed Web of Science ®Google Scholar
• Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol 2018;6(4):275-286
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocrine Rev 2011;32:515-31
   PubMed Web of Science ®Google Scholar
• Dias S, Sutton AJ, Ades AE, et al. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making 2013;33:607-17
   PubMed Web of Science ®Google Scholar
• Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417-28
   PubMed Web of Science ®Google Scholar
• Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 2012;308:1246-53
   PubMed Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24
   PubMed Web of Science ®Google Scholar
• Centre for Reviews and Dissemination. Systematic review: CRD's guidance for undertaking reviews in health care. York: University of York; 2009. Available at: https://www.york.ac.uk/crd/guidance/ [Last accessed December 29, 2016]
   Google Scholar
• Higgins JPT, Deeks JJ (2011) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011], The Cochrane Collaboration. Available at: http://handbook.cochrane.org
   Google Scholar
• National Institute for Health and Care Excellence in the UK. Type 2 diabetes in adults: management. London: National Institute for Health and Care Excellence (UK); 2015. Available at: https://www.nice.org.uk/guidance/ng28/resources [Last accessed December 29, 2016]
   Google Scholar
• Jansen JP, Naci H. Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Med 2013;11:159
   PubMed Web of Science ®Google Scholar
• Spiegelhalter DJ, Best NG, Carlin BP, et al. Bayesian measures of model complexity and fit. J R Stat Soc B 2002;64:583-639
   Google Scholar
• Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44
   PubMed Web of Science ®Google Scholar
• Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129-40
   PubMed Web of Science ®Google Scholar
• Chen KW, Boyko EJ, Bergstrom RW, et al. Earlier appearance of impaired insulin secretion than of visceral adiposity in the pathogenesis of NIDDM. 5-Year follow-up of initially nondiabetic Japanese-American men. Diabetes Care 1995;18:747-53
   PubMed Web of Science ®Google Scholar
• Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nature Rev Endocrinol 2013;9:13-27
   PubMed Web of Science ®Google Scholar
• Webb N, Orme M, Witkowski M, et al. A network meta-analysis comparing semaglutide once-weekly with other GLP-1 receptor agonists in Japanese patients with type 2 diabetes. Diabetes Ther 2018 March 24. doi: 10.1007/s13300-018-0397-1
   Web of Science ®Google Scholar
• Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33
   PubMed Web of Science ®Google Scholar
• Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012;97:1020-31
   PubMed Web of Science ®Google Scholar
• Haring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9
   PubMed Web of Science ®Google Scholar
• Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013;56:2582-92
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Lewin A, Patel S, et al. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. Diabetes Care 2015;38:384-93
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention [Internet], 2008. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf [Accessed December 29, 2016]
   Google Scholar
• Association AD. Standards of medical care in diabetes-2017: summary of revisions. Diabetes Care 2017;40(Suppl 1):S4-S5. doi: 10.2337/dc17-S003
   PubMedGoogle Scholar
• Sherwood NE, Jeffery RW, French SA, et al. Predictors of weight gain in the Pound of Prevention study. Int J Obes Relat Metab Disord 2000;24:395-403
   PubMed Web of Science ®Google Scholar
• Stevens J, Truesdale KP, McClain JE, et al. The definition of weight maintenance. Int J Obesity 2006;30:391-9
   PubMed Web of Science ®Google Scholar
• Potts JE, Gray LJ, Brady EM, et al. The effect of glucagon-like peptide 1 receptor agonists on weight loss in type 2 diabetes: a systematic review and mixed treatment comparison meta-analysis. PloS One 2015;10:e0126769
   PubMed Web of Science ®Google Scholar
• Liu SC, Tu YK, Chien MN, et al. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obesity Metab 2012;14:810-20
   PubMed Web of Science ®Google Scholar
• McIntosh B, Cameron C, Singh SR, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011;5:e35-48
   PubMedGoogle Scholar
• Reboldi G, Gentile G, Angeli F, et al. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011;29:1253-69
   PubMed Web of Science ®Google Scholar
• Turnbull F, Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-35
   PubMed Web of Science ®Google Scholar
• Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014;8:262-75.e9
   PubMed Web of Science ®Google Scholar
• Mearns ES, Sobieraj DM, White CM, et al. Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis. PLoS One 2015;10:e0125879
   PubMed Web of Science ®Google Scholar